European Union Approves Akebia's Oral Anemia Drug, Vafseo
European Regulatory Approval and Indication
The European Commission approved Vafseo (vadadustat) on April 24, 2023, for the treatment of symptomatic anemia in adult patients with chronic kidney disease undergoing chronic maintenance dialysis. The European Medicines Agency (EMA)'s Committee for Medicinal Products for Human Use (CHMP) had adopted a positive opinion on February 23. The marketing authorization holder is MEDICE Arzneimittel Pütter, a German company. Akebia Therapeutics (AKBA) has successfully transitioned a regulatory-stage candidate into an approved drug for the European market. However, the approval is limited to dialysis patients, excluding the non-dialysis chronic kidney disease market.
Mechanism of Action and Clinical Evidence
Vafseo, with the generic name vadadustat, is an oral once-daily medication that inhibits prolyl hydroxylase (HIF-PH), thereby promoting endogenous erythropoietin production and iron mobilization. The EMA evaluation was primarily based on the global Phase 3 INNO2VATE study, which involved approximately 4,000 dialysis patients. The study demonstrated that Vafseo was non-inferior to darbepoetin alfa in terms of hemoglobin correction and maintenance. Major adverse cardiovascular events (MACE) also met the pre-specified EMA non-inferiority criteria. The oral administration offers the advantage of reducing the burden on dialysis centers related to intravenous and subcutaneous injections. However, monitoring for thromboembolic events and hepatotoxicity will influence the adoption rate.
Competitive Landscape and Market Potential
The standard of care in Europe includes erythropoiesis-stimulating agents (ESAs) such as epoetin alfa (Epogen, Eprex), darbepoetin alfa (Aranesp), and methoxy polyethylene glycol-epoetin beta (Mircera). The direct oral HIF-PH competitor is Evrenzo (roxadustat), marketed by Astellas Pharma (4503) in Europe. Vafseo must compete on safety, reimbursement, and convenience of administration within the same class, rather than solely on its novel mechanism. Akebia estimates that there are over 325,000 patients with chronic kidney disease on dialysis in Europe who could benefit from the treatment, and the U.S. market for the same dialysis anemia population is estimated at approximately USD 1 billion annually based on current ESA pricing. European sales will be sequentially generated based on country-by-country price negotiations and reimbursement approvals, with MEDICE launching in Germany, Austria, Switzerland, and the Netherlands in 2024.
Global Regulatory History and Commercialization Structure
In Japan, the Ministry of Health, Labour and Welfare approved Vafseo for both dialysis and non-dialysis anemia on June 29, 2020, and it is marketed by Mitsubishi Tanabe Pharma. In the United States, the FDA issued a Complete Response Letter (CRL) on March 29, 2022, citing the failure of non-dialysis patients to meet the MACE non-inferiority endpoint, as well as concerns about thrombotic events in dialysis patients and drug-induced liver injury. However, after narrowing the indication to adult patients on dialysis for at least three months, the FDA approved Vafseo on March 27, 2024. In Europe, Akebia granted MEDICE exclusive commercialization rights for the European Economic Area, the United Kingdom, Switzerland, and Australia in May 2023. The agreement includes an upfront payment of USD 10 million, potential commercial milestone payments of up to USD 100 million, and tiered royalties of 10% to 30% of net sales, creating a structure where the approval value translates into cash and long-term royalties.
The European approval provides access to approximately 325,000 target dialysis patients and country-by-country reimbursement markets. For Akebia, this translates into an upfront payment of USD 10 million, potential commercial milestone payments of up to USD 100 million, and tiered royalties of 10% to 30% of net sales. The non-inferiority of Vafseo to darbepoetin alfa in terms of hemoglobin and MACE in the Phase 3 INNO2VATE study forms the basis for approval, but actual market share will be determined by safety management and pricing compared to Evrenzo and existing ESAs such as Epogen, Aranesp, and Mircera. In the short term, MEDICE's country-by-country reimbursement expansion and launch speed will be key to royalty growth. In the long term, the extent to which oral HIF-PH agents replace intravenous ESAs will determine the company's value. The FDA's 2022 CRL, followed by the 2024 approval limited to patients on dialysis for at least three months, demonstrates both the regulatory validation and the clear safety hurdle for expanding the indication to non-dialysis patients.
Source: EMA (ema)